# EUropean Pharmacogenetics of AntiCoagulant Therapy - Warfarin

> **NCT01119300** · PHASE4 · COMPLETED · sponsor: **Utrecht Institute for Pharmaceutical Sciences** · enrollment: 455 (actual)

## Conditions studied

- Venous Thromboembolism
- Atrial Fibrillation

## Interventions

- **OTHER:** Genotype-guided dosing algorithm
- **OTHER:** Standard care

## Key facts

- **NCT ID:** NCT01119300
- **Lead sponsor:** Utrecht Institute for Pharmaceutical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 455 (ACTUAL)
- **Last updated:** 2014-12-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01119300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01119300, "EUropean Pharmacogenetics of AntiCoagulant Therapy - Warfarin". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01119300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*